Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

APOE genotype and cognitive decline in a middle-aged cohort.

Blair CK, Folsom AR, Knopman DS, Bray MS, Mosley TH, Boerwinkle E; Atherosclerosis Risk in Communities (ARIC) Study Investigators.

Neurology. 2005 Jan 25;64(2):268-76.

PMID:
15668424
2.

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM.

JAMA. 1997 Oct 22-29;278(16):1349-56.

PMID:
9343467
3.

Apolipoprotein E ε4 and later-life decline in cognitive function and grip strength.

Batterham PJ, Bunce D, Cherbuin N, Christensen H.

Am J Geriatr Psychiatry. 2013 Oct;21(10):1010-9. doi: 10.1016/j.jagp.2013.01.035. Epub 2013 Feb 6.

PMID:
23567378
4.

The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging.

Bretsky P, Guralnik JM, Launer L, Albert M, Seeman TE; MacArthur Studies of Successful Aging.

Neurology. 2003 Apr 8;60(7):1077-81.

PMID:
12682309
5.

Association between apolipoprotein E ε4 and longitudinal cognitive decline: nested case-control study among chinese community-dwelling elders.

Ma F, Wang J, Miao R, Zhao W, Wang Q.

Neuropsychobiology. 2011;64(2):102-9. doi: 10.1159/000324991. Epub 2011 Jun 21.

PMID:
21701228
6.

APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging.

Bunce D, Fratiglioni L, Small BJ, Winblad B, Bäckman L.

Neurology. 2004 Sep 14;63(5):816-21.

PMID:
15365129
7.

The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons.

Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L.

JAMA. 1999 Jul 7;282(1):40-6.

PMID:
10404910
8.

Apolipoprotein E genotype, vascular risk and early cognitive impairment in an African Caribbean population.

Stewart R, Russ C, Richards M, Brayne C, Lovestone S, Mann A.

Dement Geriatr Cogn Disord. 2001 Jul-Aug;12(4):251-6.

PMID:
11351136
9.

The relationship of APOE genotype to cognitive functioning in older African-American and Caucasian community residents.

Fillenbaum GG, Landerman LR, Blazer DG, Saunders AM, Harris TB, Launer LJ.

J Am Geriatr Soc. 2001 Sep;49(9):1148-55.

PMID:
11559372
10.

APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model.

Martins CA, Oulhaj A, de Jager CA, Williams JH.

Neurology. 2005 Dec 27;65(12):1888-93.

PMID:
16380608
11.

Apolipoprotein epsilon4 allele status, depressive symptoms, and cognitive decline in middle-aged and elderly persons without dementia.

Lavretsky H, Ercoli L, Siddarth P, Bookheimer S, Miller K, Small G.

Am J Geriatr Psychiatry. 2003 Nov-Dec;11(6):667-73.

12.

Gene-behavior interaction of depressive symptoms and the apolipoprotein E {varepsilon}4 allele on cognitive decline.

Rajan KB, Wilson RS, Skarupski KA, Mendes de Leon CF, Evans DA.

Psychosom Med. 2014 Feb;76(2):101-8. doi: 10.1097/PSY.0000000000000029. Epub 2014 Jan 16.

13.

APOE ε4 and the risk for Alzheimer disease and cognitive decline in African Americans and Yoruba.

Hendrie HC, Murrell J, Baiyewu O, Lane KA, Purnell C, Ogunniyi A, Unverzagt FW, Hall K, Callahan CM, Saykin AJ, Gureje O, Hake A, Foroud T, Gao S.

Int Psychogeriatr. 2014 Jun;26(6):977-85. doi: 10.1017/S1041610214000167. Epub 2014 Feb 24.

14.

Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease.

Craft S, Teri L, Edland SD, Kukull WA, Schellenberg G, McCormick WC, Bowen JD, Larson EB.

Neurology. 1998 Jul;51(1):149-53.

PMID:
9674794
15.

Cognitive resilience to apolipoprotein E ε4: contributing factors in black and white older adults.

Kaup AR, Nettiksimmons J, Harris TB, Sink KM, Satterfield S, Metti AL, Ayonayon HN, Yaffe K; Health, Aging, and Body Composition (Health ABC) Study.

JAMA Neurol. 2015 Mar;72(3):340-8. doi: 10.1001/jamaneurol.2014.3978.

16.

Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population.

Yip AG, Brayne C, Easton D, Rubinsztein DC; Medical Research Council Cognitive Function Ageing Study (MRC CFAS).

J Med Genet. 2002 Sep;39(9):639-43.

17.

Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population.

Qiu C, Winblad B, Fratiglioni L.

Neurol Res. 2006 Sep;28(6):650-6.

PMID:
16945218
18.

APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment.

Ballard CG, Morris CM, Rao H, O'Brien JT, Barber R, Stephens S, Rowan E, Gibson A, Kalaria RN, Kenny RA.

Neurology. 2004 Oct 26;63(8):1399-402.

PMID:
15505155
19.

APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging.

Klages JD, Fisk JD, Rockwood K.

Dement Geriatr Cogn Disord. 2003;15(1):1-5.

PMID:
12457072
20.

Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans.

Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, Brensinger CM, Newcomb CW, Whitehead AS.

Pharmacogenomics J. 2008 Feb;8(1):53-60. Epub 2007 Feb 27.

PMID:
17325732

Supplemental Content

Support Center